Latest Blogs, Articles, and More
The FDA has granted a breakthrough therapy designation to the immunotherapy drug Keytruda (pembrolizumab) for the treatment of patients with non-small cell lung cancer.
In September, The Ohio State University Comprehensive Cancer Center, collaborating with the Department of Emergency Medicine, opened a fully integrated cancer emergency department at the new James Cancer Hospital to care for patients who develop emergencies caused by their cancers.
Preliminary data from a phase 2 trial demonstrates that a combination of the PARP inhibitor veliparib and chemotherapy benefits patients with squamous cell non-small cell lung cancer.
Being a parent affects EVERY decision in my life, even the ones regarding my cancer care.
Recently approved Akynzeo prevents common side effect with a combination approach